Lurasidone response in bipolar type I depression with childhood trauma exposure

dc.contributor.authorHernán F Guillen-Burgos
dc.contributor.authorJuan F. Gálvez‐Flórez
dc.contributor.authorSergio Moreno
dc.contributor.authorRoger S McIntyre
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T19:34:53Z
dc.date.available2026-03-22T19:34:53Z
dc.date.issued2025
dc.description.abstractThis study provides evidence that CT, particularly PA, attenuates the antidepressant effects of lurasidone in BD type I depression, leading to lower response and remission rates in both monotherapy and combination therapy with lithium. These findings underscore the clinical importance of screening for CT in BD to guide personalized treatment strategies. Identifying trauma history may help clinicians optimize treatment selection, considering the potential need for combination pharmacotherapy and adjunctive trauma-focused psychotherapeutic interventions to improve outcomes in this vulnerable population.
dc.identifier.doi10.1093/ijnp/pyaf020
dc.identifier.urihttps://doi.org/10.1093/ijnp/pyaf020
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/76891
dc.language.isoen
dc.publisherUniversity of Oxford
dc.relation.ispartofThe International Journal of Neuropsychopharmacology
dc.sourceUniversidad Simón Bolívar
dc.subjectLurasidone
dc.subjectBipolar disorder
dc.subjectDepression (economics)
dc.subjectMedicine
dc.subjectClinical Global Impression
dc.subjectInternal medicine
dc.subjectPsychiatry
dc.titleLurasidone response in bipolar type I depression with childhood trauma exposure
dc.typearticle

Files